This morning Sanofi-Aventis and Vical announced that their late-stage candidate, Temusi (NV1-FGF), failed a phase III program in patients with severe peripheral arterial disease (PAD). The 525-patient program was designed to show superiority of Temusi versus placebo in preventing amputations and death in patients with Critical Limb Ischemia (CLI), the most advanced form of PAD. [...]